Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas

Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas

Abstract Neurofibromatosis type 1 (NF1), the most common tumor predisposition syndrome, occurs when NF1 gene variants result in loss of neurofibromin, a negative regulator of RAS activity. Plexiform neurofibromas (PN) are peripheral nerve sheath tumors that develop in patients with NF1 and are assoc...

Full description

Bibliographic Details
Main Authors: Amy E. Armstrong, Allan J. Belzberg, John R. Crawford, Angela C. Hirbe, Zhihong J. Wang
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Cancer
Subjects:
Neurofibromatosis type 1
Plexiform neurofibroma
MEK inhibitors
Surgery
Clinical decision making
Online Access:https://doi.org/10.1186/s12885-023-10996-y

Internet

https://doi.org/10.1186/s12885-023-10996-y

Similar Items